Researchers reporting in the journal Cell have mapped how certain proteins from the bloodstream cross the blood-brain barrier, and found that this route is disrupted early in a mouse model of Alzheimer's disease. The team, drawn from Gladstone Institutes, the University of California, San Francisco, the Buck Institute for Research on Aging, Emory University and institutions in Hong Kong, focused on apolipoprotein A1 (APOA1), a protein produced mainly by the liver.
The blood-brain barrier normally restricts what enters the brain while letting in necessary proteins and other substances. The authors note that more than 98% of small-molecule drugs and most biologics cannot cross it, which is one reason treating neurological disorders has been so difficult. To find which blood proteins do get through, the researchers tagged circulating proteins in mice, tracked them into brain tissue and identified 92 that entered the brain parenchyma. Most of these came from the liver, fat tissue and intestine.
APOA1 was taken up mainly by astrocytes, support cells in the brain. Experiments showed that brain endothelial cells pulled it in through a receptor called SR-B1, and that once inside, it handed off to a second receptor, ABCA1, on astrocytes. In the 5xFAD mouse model, both the delivery and cellular uptake of APOA1 were reduced at an early stage, even without a broad breakdown of the barrier itself.
When the researchers raised APOA1 production in the livers of 5xFAD mice, levels rose in blood and brain, lipid buildup and inflammatory marker IL-1beta fell in the brain, and synaptic density increased in the hippocampus and cortex. Some amyloid measures dropped, though others did not change. The mice also showed less hyperactivity and better performance on some memory tests, while a different memory task was unchanged.
The authors describe the liver-plasma-brain APOA1 pathway as a potential therapeutic target. That claim rests on mouse work, and the authors state that it remains to be seen whether these mechanisms and effects apply to people or to other neurological conditions.